Federated Hermes’s Citius Pharmaceuticals CTXR Stock Holding History

Federated Hermes’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10	Closed	-$1K	–	2237
2021 Q2	$1K	Buy	+10	New	+$601	﹤0.01%	2125

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Federated Hermes's CTXR Position: Q3 2021 in Review

Federated Hermes sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 10 shares — an estimated $1K sold.

Federated Hermes first reported a position in CTXR in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

Federated Hermes reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Federated Hermes sold 10 Citius Pharmaceuticals shares in Q3 2021, an estimated $1K.
Federated Hermes first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Federated Hermes's Citius Pharmaceuticals position peaked at $1K in Q2 2021.
71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on Federated Hermes's 13F filing for Q3 2021, filed 15 Nov 2021.